Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-101 in Familial Hypercholesterolemia
NCT06458010Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YOLT-101 in familial hypercholesterolemia (FH), sponsored by Renji Hospital. Primary endpoint: Safety evaluation of YOLT-101 at 52 weeks. Started May 2024; status: recruiting.
02
Drugs
YOLT-101
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT06458010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06458010.